SCHEMBL8845783

SCHEMBL8845783

CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(=O)NC(=O)c1ccc2ccccc2n1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 9/20 0.79
ABCB1 P08183 3/20 0.79
ABCC4 O15439 2/20 0.79
ABCB11 O95342 2/20 0.79
TACR2 P21452 2/20 0.79
TBXAS1 P24557 2/20 0.79
OPRM1 P35372 2/20 0.79
OPRD1 P41143 2/20 0.79
OPRK1 P41145 2/20 0.79
SLC6A3 Q01959 2/20 0.79
KCNH2 Q12809 2/20 0.79
ABCG2 Q9UNQ0 2/20 0.79
ABCC3 O15438 1/20 0.79
CACNA1F O60840 1/20 0.79
HTR1A P08908 1/20 0.79
DRD2 P14416 1/20 0.79
DRD3 P35462 1/20 0.79
AVPR1A P37288 1/20 0.79
HTR2B P41595 1/20 0.79
CACNA1D Q01668 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Saquinavir SCHEMBL13575784 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL8584252 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL13953012 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL8584255 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL20451344 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL1176566 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL6881 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL1976548 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL21683360 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL29357501 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0810873-A1 ANTIVIRAL COMBINATIONS OF BCH-189 AND RITONAVIR GLAXO GROUP LIMITED (GB) 1997-12-10 EP disclosed
US-5627186-A Antiviral combinations GLAXO GROUP LIMITED (GB) 1997-05-06 US disclosed
US-5610307-A Direct isolution of optically pure (3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid THE NUTRA SWEET COMPANY (US) 1997-03-11 US disclosed
WO-1996026734-A1 ANTIVIRAL COMBINATIONS OF BCH-189 AND RITONAVIR GLAXO GROUP LIMITED (GB) 1996-09-06 WO disclosed
EP-0513917-B1 Antiviral combinations containing nucleoside analogs GLAXO GROUP LTD (GB) 1995-12-20 EP disclosed
EP-0513917-A1 Antiviral combinations containing nucleoside analogs GLAXO GROUP LIMITED (GB) 1992-11-19 EP disclosed